372
Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratifi cation of the adnexal mass
using a multivariate index assay. Gynecol Oncol. 2013;128:252–9.
Brower SL, Fensterer JE, Bush JE. The ChemoFx assay: an ex vivo chemosensitivity and resis-
tance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol.
2008;414:57–78.
Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response
in vitro and in vivo. Proc Natl Acad Sci. 2008;105:9053–8.
Burington B, Yue P, Shi X, et al. CD40 pathway activation status predicts response to CD40 ther-
apy in diffuse large B cell lymphoma. Sci Transl Med 2011;3:74ra22.
Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lympho-
cytic leukemia. NEJM. 2013;369:32–42.
Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared
with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation
Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–14.
Cappuzzo F, Sacconi A, Landi L, et al. MicroRNA signature in metastatic colorectal cancer
patients treated with anti-EGFR monoclonal antibodies. Clin Colorectal Cancer 2014;13:37–
45.e4.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 2006;295:2492–502.
Carter SL, Eklund AC, Kohane IS, et al. A signature of chromosomal instability inferred from gene
expression profi les predicts clinical outcome in multiple human cancers. Nat Genet.
2006;38:1043–8.
Chakrabarty A, Sanchez V, Kuba MG, et al. Feedback upregulation of HER3 (ErbB3) expression
and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A.
2012;109:2718–23.
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma
with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
Chen HY, Yu SL, Chen CH, et al. A fi ve-gene signature and clinical outcome in non–small-cell
lung cancer. NEJM. 2007;356:11–20.
Cheng H, Qin Q, Sun X, et al. Predictive effect of XPA and XPD polymorphisms on survival of
advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional
(3-D), polyacrylamide gel-based DNA microarray method. Technol Cancer Res Treat.
2013;12:473–82.
Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance
to ALK inhibitors. N Engl J Med. 2010;363:1734–9.
Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes
after allogeneic stem-cell transplantation. Blood. 2007;109:4698–707.
Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detec-
tion of minimal residual disease by standardized WT1 assay to enhance risk stratifi cation in
acute myeloid leukemia: a European LeukemiaNet Study. J Clin Oncol. 2009;27:5195–201.
Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals
mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077–80.
Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med.
2013;369:2369–71.
Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro
Oncol. 2010;12:49–57.
Cowin PA, George J, Fereday S, et al. LRP1B deletion in high-grade serous ovarian cancers is
associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res.
2012;72:4060–73.
Craig DW, O’Shaughnessy JA, Kiefer JA, et al. Genome and transcriptome sequencing in prospec-
tive triple negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther.
2012;12:104–16.
Cunningham L, Aplenc R. Pharmacogenetics of acute lymphoblastic leukemia treatment response.
Expert Opin Pharmacother. 2007;8:2519–31.
10 Personalized Therapy of Cancer